Fresenius Medical Care (NYSE:FMS) Stock Rating Upgraded by Bank of America

Bank of America upgraded shares of Fresenius Medical Care (NYSE:FMS) from an underperform rating to a neutral rating in a research report sent to investors on Monday, MarketBeat.com reports.

A number of other equities analysts also recently commented on the stock. Truist Financial boosted their target price on shares of Fresenius Medical Care from $22.00 to $23.00 and gave the stock a “hold” rating in a report on Monday, October 7th. Berenberg Bank started coverage on shares of Fresenius Medical Care in a research report on Wednesday, November 6th. They set a “buy” rating and a $25.60 target price for the company. Finally, StockNews.com started coverage on shares of Fresenius Medical Care in a research note on Thursday, November 28th. They issued a “strong-buy” rating for the company. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, one has given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $24.30.

Fresenius Medical Care Trading Up 3.5 %

Shares of NYSE:FMS opened at $22.79 on Monday. The company has a current ratio of 1.37, a quick ratio of 1.02 and a debt-to-equity ratio of 0.42. The company has a market capitalization of $13.37 billion, a PE ratio of 18.83, a P/E/G ratio of 1.01 and a beta of 0.91. Fresenius Medical Care has a 12-month low of $17.93 and a 12-month high of $22.83. The business’s fifty day simple moving average is $20.97 and its 200-day simple moving average is $20.30.

Institutional Trading of Fresenius Medical Care

A number of institutional investors have recently bought and sold shares of FMS. Allworth Financial LP raised its holdings in shares of Fresenius Medical Care by 53.1% in the third quarter. Allworth Financial LP now owns 1,675 shares of the company’s stock worth $36,000 after buying an additional 581 shares during the last quarter. Mercer Global Advisors Inc. ADV raised its stake in shares of Fresenius Medical Care by 4.5% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 14,581 shares of the company’s stock valued at $278,000 after buying an additional 624 shares during the last quarter. Signaturefd LLC lifted its holdings in shares of Fresenius Medical Care by 8.4% in the 2nd quarter. Signaturefd LLC now owns 8,713 shares of the company’s stock valued at $166,000 after buying an additional 672 shares during the period. MML Investors Services LLC boosted its stake in shares of Fresenius Medical Care by 5.3% in the third quarter. MML Investors Services LLC now owns 15,019 shares of the company’s stock worth $320,000 after buying an additional 753 shares during the last quarter. Finally, Ritholtz Wealth Management grew its holdings in Fresenius Medical Care by 2.5% during the second quarter. Ritholtz Wealth Management now owns 36,901 shares of the company’s stock worth $704,000 after acquiring an additional 895 shares during the period. 8.25% of the stock is currently owned by institutional investors and hedge funds.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.